Activation of natural killer cells by rituximab in granulomatosis with polyangiitis
Abstract Objective In the last few years, anti-CD20 antibody rituximab profoundly changed the therapeutic landscape of granulomatosis with polyangiitis (GPA). Here, we investigated whether natural killer (NK) cells may play a role in rituximab’s mechanism of action in GPA. Methods B cell depletion,...
Main Authors: | Doris Urlaub, Shuyang Zhao, Norbert Blank, Raoul Bergner, Maren Claus, Theresa Tretter, Hanns-Martin Lorenz, Carsten Watzl, Wolfgang Merkt |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-12-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13075-019-2054-0 |
Similar Items
-
Granulomatosis with polyangiitis with severe lung involvement: efficacy of anti-B cell therapy with Rituximab
by: T. V. Beketova, et al.
Published: (2021-07-01) -
Ophthalmologic manifestations of granulomatosis with polyangiitis (Wegener’s granulomatosis)
by: Ya O Grusha, et al.
Published: (2015-12-01) -
Staphylococcus Aureus carriage and long-term Rituximab treatment for Granulomatosis with polyangiitis
by: Emilio Besada, et al.
Published: (2015-06-01) -
Gastrointestinal Involvement in Granulomatosis with Polyangiitis: Case Report and Review
by: Sahil Bagai, et al.
Published: (2019-01-01) -
COVID-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)
by: T. V. Beketova, et al.
Published: (2018-06-01)